The biotech bull is back, and buysiders believe this market has staying power for the first time in nearly five years. On a special episode of the BioCentury This Week podcast, Director of Biopharma Intelligence Stephen Hansen and colleagues discuss Hansen’s 2026 Public Markets Preview, which found interest rates, policy in Washington and fundamentals finally aligning and a wave of launches and M&A that could keep capital flowing into the sector.
View full story: https://www.biocentury.com/article/658154
#BiotechBullMarket #PublicMarkets #BiotechMA #IPOOutlook #FDApolicy
00:00 - Introduction
00:41 - Market Sentiment
07:55 - Biotech's Next Wave
14:47 - Lingering Concerns
23:29 - IPOs
26:47 - M&A
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
